[Hypogammaglobulinemia and immunodeficiency in multiple myeloma and chronic lymphoid leukemia]

Area of Science:

• Hematology
• Immunology
• Oncology

Context:

• Infections are a primary cause of morbidity and mortality in patients diagnosed with lymphoproliferative malignancies, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
• The etiology of infections in these patients is complex, often stemming from a combination of disease-related and treatment-related factors.
• Advances in therapeutic strategies have significantly improved survival rates for patients with lymphoproliferative malignancies.

Purpose:

• To highlight the significant challenge infections pose to patients with multiple myeloma and chronic lymphocytic leukemia.
• To underscore the link between improved survival and the rising incidence of secondary immune deficiencies (SID) in these hematologic malignancies.

Summary:

• Infections represent a critical threat to patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), contributing significantly to illness and death.
• While novel treatments enhance survival for these cancers, they concurrently increase the risk of secondary immune deficiencies (SID).
• Understanding the multifactorial causes of infection is crucial for managing patients with lymphoproliferative malignancies.

Impact:

• Recognizing the increased risk of SID in MM and CLL patients undergoing new therapies is essential for clinical management.
• This understanding can guide the development of preventative strategies and supportive care to mitigate infection-related complications.
• Improved patient outcomes in lymphoproliferative malignancies necessitate a proactive approach to managing infection risks and immune status.